Organizing Pneumonia Induced by Inhalation of Interferon in the Treatment of Lung Adenocarcinoma: One Case Report and Literature Review_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

DuanLinli , ZhouYing , ZhangNuofu ,  LiuChunli

The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, 510120, China;

Corresponding?author：

LiuChunli, Email: chunli@gird.cn

Keywords：

Aerosolized interferon; Drug-induced lung injury; Lung adenocarcinoma

DOI：

10.7507/1671-6205.2015140

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the clinical manifestation, radiological, pathological features and treatment of organizing pneumonia (OP) induced by aerosolized recombinant super compound interferon (rSIFN-co). Methods Clinical features and related laboratory examinations of a patient with OP developing after initiation of rSIFN-co for treatment of lung adenocarcinoma were analyzed, and the relevant literature was reviewed. Results A 48-year-old man developed cough, fevers, shortness of breath and weight loss, shortly half a month after initiation of therapy with rSIFN-co for lung adenocarcinoma. Chest high resolution computerized tomography (HRCT) showed multiple lung infection diseases. However, the anti-infection treatment was invalid. Lung tissue biopsy by bronchofibroscope was consistent with OP. After discontinuation of rSIFN-co and receiving pulse corticosteroid therapy followed by oral methylprednisolone, the pneumonic symptoms and chest manifestations markedly improved. After eight-month follow-up, the patient's condition was stable. The relative literature screening from Pubmed and Wanfangdata was implemented, but there was no report about OP caused by aerosolized rSIFN-co for lung adenocarcinoma. Conclusion This report suggests that treatment with aerosolized rSIFN-co for lung adenocarcinoma may induce OP, a rare complication, and clinicians should have vigilance on it.

Citation： DuanLinli, ZhouYing, ZhangNuofu, LiuChunli. Organizing Pneumonia Induced by Inhalation of Interferon in the Treatment of Lung Adenocarcinoma: One Case Report and Literature Review. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(6): 583-587. doi: 10.7507/1671-6205.2015140 Copy

1.	?Strober W, Fuss I, Kitani A. Regulation of experimental mucosal inflammation. Acta Odontol Scand,2001,59:244-247.
2.	Sun H, Gutierrez P, Jackson MJ, et al. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother,2000,23:208-214.
3.	Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med,2001,7:1159-1162.
4.	陳妍,何躍東,潘小玲,等.重組高效復合干擾素增強宮頸癌CaSki細胞對CTL殺傷作用敏感性及機制的研究.四川大學學報(醫學版),2008,39:715-718.
5.	鄭潔,呂青,魏大鵬.重組復合高效干擾素抗人乳腺癌細胞的體外實驗研究.四川大學學報(醫學版),2010,41:29-34,48.
6.	譚秀梅,何凱,高德紅,等.新型重組高效復合干擾素對卵巢癌細胞的生長抑制及促凋亡作用.中國性科學,2011,20:5-7,9.
7.	Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis:report of two cases. Can Respir J,2007,14:167-170.
8.	Smith J. Erlotinib:small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther,2005,27:1513-1534.
9.	Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol,2002,107:133-144.
10.	Ando S, Kawai K, Kuriyagawa K, et al. Extremely acute exacerbation of interstitial Pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma. Int J Clin Oncol,2009,14:171-173.
11.	施舉紅,嚴曉偉,許文兵,等.藥物性肺損傷的臨床診斷與治療.中華結核和呼吸雜志,2007,30:161-166.
12.	Patel M, Ezzat W, Pauw KL, et al. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Eur J Haematol,2001,67:318-321.

1. ?Strober W, Fuss I, Kitani A. Regulation of experimental mucosal inflammation. Acta Odontol Scand,2001,59:244-247.
2. Sun H, Gutierrez P, Jackson MJ, et al. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother,2000,23:208-214.
3. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med,2001,7:1159-1162.
4. 陳妍,何躍東,潘小玲,等.重組高效復合干擾素增強宮頸癌CaSki細胞對CTL殺傷作用敏感性及機制的研究.四川大學學報(醫學版),2008,39:715-718.
5. 鄭潔,呂青,魏大鵬.重組復合高效干擾素抗人乳腺癌細胞的體外實驗研究.四川大學學報(醫學版),2010,41:29-34,48.
6. 譚秀梅,何凱,高德紅,等.新型重組高效復合干擾素對卵巢癌細胞的生長抑制及促凋亡作用.中國性科學,2011,20:5-7,9.
7. Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis:report of two cases. Can Respir J,2007,14:167-170.
8. Smith J. Erlotinib:small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther,2005,27:1513-1534.
9. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol,2002,107:133-144.
10. Ando S, Kawai K, Kuriyagawa K, et al. Extremely acute exacerbation of interstitial Pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma. Int J Clin Oncol,2009,14:171-173.
11. 施舉紅,嚴曉偉,許文兵,等.藥物性肺損傷的臨床診斷與治療.中華結核和呼吸雜志,2007,30:161-166.
12. Patel M, Ezzat W, Pauw KL, et al. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Eur J Haematol,2001,67:318-321.

Chinese Journal of Respiratory and Critical Care Medicine

Organizing Pneumonia Induced by Inhalation of Interferon in the Treatment of Lung Adenocarcinoma: One Case Report and Literature Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content